Nonresolving inflammation.

Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol (2011) 12.21

Macrophage biology in development, homeostasis and disease. Nature (2013) 8.28

Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 7.26

A genomic storm in critically injured humans. J Exp Med (2011) 6.67

The immunology of stroke: from mechanisms to translation. Nat Med (2011) 6.53

Sepsis definitions: time for change. Lancet (2013) 5.63

IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer (2010) 4.08

Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol (2013) 3.85

Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol (2011) 3.68

Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science (2013) 3.64

Regulation of the inflammatory response in cardiac repair. Circ Res (2012) 3.21

Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther (2011) 3.06

Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol (2011) 2.92

A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk. Nature (2010) 2.88

MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol (2015) 2.85

Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity (2011) 2.47

Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions. Circulation (2011) 2.45

Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood (2012) 2.37

The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab (2012) 2.36

Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1β. Nat Immunol (2012) 2.34

Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology (2011) 2.31

Mycobacterium tuberculosis exploits human interferon γ to stimulate macrophage extracellular trap formation and necrosis. J Infect Dis (2013) 2.27

Spatiotemporal photolabeling of neutrophil trafficking during inflammation in live zebrafish. J Leukoc Biol (2011) 2.22

Reflex principles of immunological homeostasis. Annu Rev Immunol (2012) 2.04

Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol (2013) 1.96

Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res (2012) 1.94

Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res (2010) 1.89

MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J (2010) 1.87

Neural reflexes in inflammation and immunity. J Exp Med (2012) 1.87

Macrophage polarization: an opportunity for improved outcomes in biomaterials and regenerative medicine. Biomaterials (2012) 1.81

Artery Tertiary Lymphoid Organs Control Aorta Immunity and Protect against Atherosclerosis via Vascular Smooth Muscle Cell Lymphotoxin β Receptors. Immunity (2015) 1.74

Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta (2010) 1.72

Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J (2011) 1.72

Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev (2012) 1.71

Inflammasome-dependent pyroptosis and IL-18 protect against Burkholderia pseudomallei lung infection while IL-1β is deleterious. PLoS Pathog (2011) 1.68

Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer. Gastroenterology (2013) 1.67

Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: receptor-dependent actions. Arterioscler Thromb Vasc Biol (2012) 1.67

Human CD68 promoter GFP transgenic mice allow analysis of monocyte to macrophage differentiation in vivo. Blood (2014) 1.66

Recent insights into the cellular biology of atherosclerosis. J Cell Biol (2015) 1.60

Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol (2011) 1.52

Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation (2014) 1.51

Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation. Proc Natl Acad Sci U S A (2012) 1.49

Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. Nat Immunol (2012) 1.49

NF-κB-mediated degradation of the coactivator RIP140 regulates inflammatory responses and contributes to endotoxin tolerance. Nat Immunol (2012) 1.48

The Effect of Sustained Inflammation on Hepatic Mevalonate Pathway Results in Hyperglycemia. Cell (2016) 1.47

Molecular functions of syndecan-1 in disease. Matrix Biol (2011) 1.47

Tumor necrosis factor induces GSK3 kinase-mediated cross-tolerance to endotoxin in macrophages. Nat Immunol (2011) 1.46

Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab (2013) 1.45

Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis. J Clin Invest (2015) 1.43

Homeostasis, inflammation, and disease susceptibility. Cell (2015) 1.41

Understanding immunity requires more than immunology. Nat Immunol (2010) 1.38

Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res (2014) 1.36

Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. Curr Opin Clin Nutr Metab Care (2010) 1.36

Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol (2015) 1.34

Medical therapies with adult stem/progenitor cells (MSCs): a backward journey from dramatic results in vivo to the cellular and molecular explanations. J Cell Biochem (2012) 1.33

HMGB1 mediates cognitive impairment in sepsis survivors. Mol Med (2012) 1.33

Gene-environment interactions in chronic inflammatory disease. Nat Immunol (2011) 1.30

TNF-alpha from inflammatory dendritic cells (DCs) regulates lung IL-17A/IL-5 levels and neutrophilia versus eosinophilia during persistent fungal infection. Proc Natl Acad Sci U S A (2011) 1.30

Microglial activation - tuning and pruning adult neurogenesis. Front Pharmacol (2012) 1.29

Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction. Circ Res (2013) 1.27

Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes (2012) 1.27

Regulation of Drosophila lifespan by JNK signaling. Exp Gerontol (2010) 1.27

Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc Natl Acad Sci U S A (2013) 1.27

Evolution of inflammatory diseases. Curr Biol (2012) 1.27

Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol Psychiatry (2012) 1.26

Particle disease: biologic mechanisms of periprosthetic osteolysis in total hip arthroplasty. Innate Immun (2012) 1.24

Lipid mediators in immune dysfunction after severe inflammation. Trends Immunol (2013) 1.24

IL-10-induced microRNA-187 negatively regulates TNF-α, IL-6, and IL-12p40 production in TLR4-stimulated monocytes. Proc Natl Acad Sci U S A (2012) 1.24

MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J Clin Invest (2013) 1.23

Inflammation in the early stages of neurodegenerative pathology. J Neuroimmunol (2011) 1.21

The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore. Trends Endocrinol Metab (2013) 1.21

The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. Brief Funct Genomics (2013) 1.20

Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem (2012) 1.19

Macrophage-specific TLR2 signaling mediates pathogen-induced TNF-dependent inflammatory oral bone loss. J Immunol (2012) 1.18

The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol Med (2014) 1.17

Two unique human decidual macrophage populations. J Immunol (2011) 1.17

The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J (2013) 1.16

Role of the inflammasome, IL-1β, and IL-18 in bacterial infections. ScientificWorldJournal (2011) 1.15

Repulsive guidance molecule-A (RGM-A) inhibits leukocyte migration and mitigates inflammation. Proc Natl Acad Sci U S A (2011) 1.15

Heme on innate immunity and inflammation. Front Pharmacol (2014) 1.15

NK cells are effectors for resolvin E1 in the timely resolution of allergic airway inflammation. J Immunol (2011) 1.13

The role of macrophages and dendritic cells in the initiation of inflammation in IBD. Inflamm Bowel Dis (2014) 1.13

Local apoptosis mediates clearance of macrophages from resolving inflammation in mice. Blood (2013) 1.12

Risk factors for pancreatic cancer: underlying mechanisms and potential targets. Front Physiol (2014) 1.10

Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye (Lond) (2011) 1.10

Self-limited versus delayed resolution of acute inflammation: temporal regulation of pro-resolving mediators and microRNA. Sci Rep (2012) 1.09

Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol (2010) 1.09

Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome. PLoS One (2012) 1.09

Resolvins: natural agonists for resolution of pulmonary inflammation. Prog Lipid Res (2010) 1.08

Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions. Proc Natl Acad Sci U S A (2012) 1.08

Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proc Natl Acad Sci U S A (2014) 1.07

Estrogen negatively regulates epithelial wound healing and protective lipid mediator circuits in the cornea. FASEB J (2011) 1.06

A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients: Discovery and Validation in Independent Cohorts. PLoS Med (2015) 1.06

Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation. Front Immunol (2012) 1.06

Inhaled carbon monoxide accelerates resolution of inflammation via unique proresolving mediator-heme oxygenase-1 circuits. J Immunol (2013) 1.06

Molecular targets for treatment of kidney fibrosis. J Mol Med (Berl) (2012) 1.06

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther (2011) 1.05

Dangkwisoo-san, an herbal medicinal formula, ameliorates acute lung inflammation via activation of Nrf2 and suppression of NF-κB. J Ethnopharmacol (2012) 1.04

Smad6-specific recruitment of Smurf E3 ligases mediates TGF-β1-induced degradation of MyD88 in TLR4 signalling. Nat Commun (2011) 1.04

Chemical mediators of inflammation and resolution in post-operative abdominal aortic aneurysm patients. Inflammation (2012) 1.04

HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock (2006) 4.53

Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell (2002) 4.08

dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science (2012) 3.72

Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med (2009) 3.32

MyD88-mediated stabilization of interferon-gamma-induced cytokine and chemokine mRNA. Nat Immunol (2006) 3.20

Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol (2007) 2.96

MyD88 primes macrophages for full-scale activation by interferon-gamma yet mediates few responses to Mycobacterium tuberculosis. J Exp Med (2003) 2.10

MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival. J Exp Med (2007) 1.74

Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J (2010) 1.44

Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med (2005) 1.40

SnapShot: Reactive Oxygen Intermediates (ROI). Cell (2010) 1.35

Microarray analysis of changes in gene expression in a murine model of chronic chagasic cardiomyopathy. Parasitol Res (2003) 1.19

Murine macrophages produce secretory leukocyte protease inhibitor during clearance of apoptotic cells: implications for resolution of the inflammatory response. J Immunol (2003) 1.15

The secretory leukocyte protease inhibitor is a type 1 insulin-like growth factor receptor-regulated protein that protects against liver metastasis by attenuating the host proinflammatory response. Cancer Res (2006) 0.99

Progranulin deficiency promotes post-ischemic blood-brain barrier disruption. J Neurosci (2013) 0.96

Secretory leukocyte protease inhibitor plays an important role in the regulation of allergic asthma in mice. J Immunol (2011) 0.92

Role of CLIC4 in the host innate responses to bacterial lipopolysaccharide. Eur J Immunol (2011) 0.92

Beneficial effects of secretory leukocyte protease inhibitor after spinal cord injury. Brain (2010) 0.88

Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function. Biochim Biophys Acta (2005) 0.87

SARM is required for neuronal injury and cytokine production in response to central nervous system viral infection. J Immunol (2013) 0.87

Delayed cutaneous wound healing in mice lacking solute carrier 11a1 (formerly Nramp1): correlation with decreased expression of secretory leukocyte protease inhibitor. J Invest Dermatol (2006) 0.86

Progranulin contributes to endogenous mechanisms of pain defense after nerve injury in mice. J Cell Mol Med (2012) 0.79

The protein Zfand5 binds and stabilizes mRNAs with AU-rich elements in their 3'-untranslated regions. J Biol Chem (2012) 0.79

SARM regulates CCL5 production in macrophages by promoting the recruitment of transcription factors and RNA polymerase II to the Ccl5 promoter. J Immunol (2014) 0.76

Abrupt expression of TLR4 in TLR4-deficient macrophages imposes a selective disadvantage: genetic evidence for TLR4-dependent responses to endogenous, nonmicrobial stimuli. J Immunol (2006) 0.75